Media

Cerenis Therapeutics Receives FDA IND Approval to Begin Studies with CER-209 in NAFLD and NASH

BONESUPPORT confirms election of Dr. Håkan Björklund as Chairman of the Board

Orexo appeal Zubsolv® US district court decision

Nordic Nanovector – Private placement successfully completed

Altimmune Announces Acceptance of HepTcell Abstract for Presentation at BSI/NVVI Congress 2016

Nordic Nanovector: Betalutin® in combination with rituximab demonstrates synergistic anti-tumour effect in preclinical non-Hodgkin lymphoma model

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Nordic Nanovector: Single-dose Betalutin® shows promising efficacy, improved duration of response and favourable safety in relapsed NHL patients

Nordic Nanovector to Present at the Nordic-American Life Sciences Conference in New York

Strongbridge Biopharma plc Announces Promotion of Fredric Cohen, M.D., to Chief Medical Officer